# EDGAR Filing Document

**Accession Number:** 0002020932
**File Stem:** 9999999995-26-000416
**Filing Date:** 2026-1
**Character Count:** 1379
**Document Hash:** eb1455570e8f80ff7211c55081f6ae66
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**9999999995-26-000416.hdr.sgml**: 20260202

**ACCESSION NUMBER**: 9999999995-26-000416

**CONFORMED SUBMISSION TYPE**: EFFECT

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260130

**DATE AS OF CHANGE**: 20260202

**EFFECTIVENESS DATE**: 20260130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Agomab Therapeutics NV
- **CENTRAL INDEX KEY:** 0002020932
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** EFFECT
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-292790
- **FILM NUMBER:** 26585496

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** POSTHOFLEI 1/6
- **CITY:** ANTWERPEN
- **PROVINCE COUNTRY:** C9
- **ZIP:** 2600
- **BUSINESS PHONE:** 32 3 302 35 30

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** POSTHOFLEI 1/6
- **CITY:** ANTWERPEN
- **PROVINCE COUNTRY:** C9
- **ZIP:** 2600

### UNITED STATES
### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## Notice of Effectiveness

**Date:** January 30, 2026

**Time:** 16:01:00

**Form Type:** F-1

---

**CIK:** 0002020932

**Company Name:** Agomab Therapeutics NV

**File Number:** 333-292790